Comparison of PRF and Corticosteroids in Impacted Third Molar Surgery

July 29, 2026 updated by: Meliz Kneebone, Final International University

Comparison of Postoperative Effects of PRF and Corticosteroid Treatments in Impacted Third Molar Surgery

This prospective, randomized interventional study aims to compare the postoperative effects of standard treatment (control), platelet-rich fibrin (PRF), and PRF combined with corticosteroid treatment in patients undergoing impacted mandibular third molar surgery. A total of 60 participants will be randomly assigned to one of three treatment groups according to the study protocol. Postoperative pain, facial swelling, and trismus will be evaluated on postoperative days 1, 2, 3, and 7. The findings of this study are expected to provide evidence regarding the effectiveness of PRF alone and PRF combined with corticosteroid treatment in reducing postoperative complications following impacted mandibular third molar surgery.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Nicosia, Cyprus, 2323
        • Recruiting
        • Final International University Faculty of Dentistry
        • Contact:
        • Principal Investigator:
          • Meliz Kneebone, DDS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patients aged 18 years and older.
  • Patients with good general health
  • Patients with complete clinical and radiographic examination (panoramic radiograph/CBCT if applicable)
  • Patients willing and able to attend all postoperative follow-up visits

Exclusion Criteria:

  • Patients with systemic diseases that may impair wound healing (e.g., uncontrolled diabetes, immunodeficiency).
  • Pregnant or breastfeeding women.
  • Patients with acute infection, abscess, or pericoronitis at the surgical site.
  • Patients with a history of allergy or contraindication to corticosteroids, local anesthetics, or prescribed medications.
  • Patients using corticosteroids, anticoagulants, immunosuppressive drugs, or bisphosphonates.
  • Patients with bleeding disorders.
  • Patients with previous radiotherapy to the head and neck region.
  • Patients unable or unwilling to comply with the study protocol or attend follow-up visits.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard Postoperative Treatment (Control)
Participants receive standard postoperative treatment following impacted mandibular third molar surgery, including amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash. No platelet-rich fibrin (PRF) or corticosteroid is administered.
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
Experimental: Platelet-Rich Fibrin (PRF)
Participants receive platelet-rich fibrin (PRF) placed into the extraction socket in addition to standard postoperative treatment consisting of amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash following impacted mandibular third molar surgery.
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
Autologous platelet-rich fibrin (PRF) prepared from the participant's venous blood by centrifugation at 3000 rpm for 10 minutes, and then placed into the extraction socket immediately after impacted mandibular third molar surgery.
Experimental: Platelet-Rich Fibrin Plus Corticosteroid
Participants receive platelet-rich fibrin (PRF) placement into the extraction socket followed by intramuscular corticosteroid administration, in addition to standard postoperative treatment consisting of amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash following impacted mandibular third molar surgery.
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
Autologous platelet-rich fibrin (PRF) prepared from the participant's venous blood by centrifugation at 3000 rpm for 10 minutes, and then placed into the extraction socket immediately after impacted mandibular third molar surgery.
Dexamethasone (8 mg/2 mL) administered as a single intramuscular injection immediately after impacted mandibular third molar surgery in addition to platelet-rich fibrin (PRF), according to the study protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Pain
Time Frame: Postoperative Days 1, 2, 3, and 7
Postoperative pain assessed using a 10-cm Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable.
Postoperative Days 1, 2, 3, and 7
Postoperative Swelling
Time Frame: Postoperative Days 1, 2, 3, and 7
Postoperative facial swelling assessed using a flexible measuring tape by recording the linear distances from the tragus to the pogonion (chin point), the tragus to the corner of the mouth, and the lateral canthus of the eye to the angle of the mandible.
Postoperative Days 1, 2, 3, and 7
Trismus
Time Frame: Postoperative Days 1, 2, 3, and 7
Trismus assessed by measuring the maximum interincisal mouth opening (mm) using a digital caliper.
Postoperative Days 1, 2, 3, and 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 3, 2024

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

July 28, 2026

First Submitted That Met QC Criteria

July 29, 2026

First Posted (Actual)

August 3, 2026

Study Record Updates

Last Update Posted (Actual)

August 3, 2026

Last Update Submitted That Met QC Criteria

July 29, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because the study was conducted as part of an academic thesis, and there is no institutional plan for sharing de-identified participant-level data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.